Business
Natera and Illumina Settle Patent Dispute
SAN CARLOS, Calif. and SAN DIEGO, May 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina
About this update from Natera, Inc.
[{"type":"text","content":"SAN CARLOS, Calif. and SAN DIEGO, May 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, and Illumina Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing platforms, today announced that they have settled their patent infringement action (\"Action\") concerning Illumina's U.S. Patent No. 9,493,831 (\"'831 Patent\") and Natera's U.S. Patent No. 8,682,592 (the \"'592 Patent\"). Terms of the settlement are included in the Form 8-K filed May 11, 2020 by Natera with the U.S. Securities & Exchange Commission.\n\n \n \n \n \n \n \n\n \nThe settlement resolves and dismisses all of the claims in the Action, including claims that relate to non-invasive prenatal testing (\"NIPT\"), occurring before the settlement date. Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. \nAdditionally, Natera has granted Illumina a non-exclusive license to Natera's '592 Patent family. The license is limited to Illumina's current technology used for massively parallel sequencing in the fields of NIPT and PGS/PGD.\nIn a joint statement, Daniel Rabinowitz, General Counsel for Natera and Charles Dadswell, General Counsel for Illumina stated, \"We believe that settling the case is in the best interests of all parties and our respective customers, employees and shareholders.\"\nAbout NateraNatera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.\nAbout IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-ba...